Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers
- Conditions
- Healthy
- First Posted Date
- 2006-12-25
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 42
- Registration Number
- NCT00415740
- Locations
- 🇩🇪
Novartis Investigative Site, Nuernberg, Germany
Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone Under Fasting Conditions in Healthy Volunteers
- Conditions
- Healthy
- First Posted Date
- 2006-12-25
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 42
- Registration Number
- NCT00415844
- Locations
- 🇩🇪
Novartis Investigative Site, Nuernberg, Germany
To Compare the Blood Level of Marketed Japanese Valsartan Tablet Formulation vs Global Valsartan Tablet Formulation in Healthy Volunteers
- Conditions
- Healthy
- First Posted Date
- 2006-12-25
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 40
- Registration Number
- NCT00415883
- Locations
- 🇮🇳
Novartis Investigative Site, Mumbai, India
Safety and Pharmacokinetics of LHT344 in Chinese Healthy Subjects
- Conditions
- Healthy
- First Posted Date
- 2006-12-22
- Last Posted Date
- 2011-01-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 12
- Registration Number
- NCT00414778
- Locations
- 🇨🇳
Novartis Investigative Site, Beijing, China
Effects of AFQ056 and Baclofen on Meal-Induced Gastroesophageal Reflux
- Conditions
- Gastroesophageal Reflux Disease
- First Posted Date
- 2006-12-22
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 34
- Registration Number
- NCT00414856
- Locations
- 🇨🇭
Novartis Investigative site, Bern, Switzerland
🇩🇪Novartis Investigative Site, Nuernberg, Germany
Effects of AFQ056 and Nicotine in Reducing Cigarette Smoking
- Conditions
- Smoking Abstinence
- First Posted Date
- 2006-12-22
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 36
- Registration Number
- NCT00414752
- Locations
- 🇩🇪
Novartis Investigative Site, Nuernberg, Germany
Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers
- Conditions
- Healthy
- First Posted Date
- 2006-12-22
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00414947
- Locations
- 🇨🇳
Novartis Investigative Site, Beijing, China
Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)
- First Posted Date
- 2006-12-21
- Last Posted Date
- 2012-07-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 820
- Registration Number
- NCT00414609
- Locations
- 🇮🇳
Novartis Healthcare Private Limited, Worli, Mumbai, India
🇵🇱Novartis Poland Sp. z o.o., Warszawa, Poland
🇭🇺Novartis Hungary, Budapest, Hungary
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
- Conditions
- Opioid-induced Constipation
- First Posted Date
- 2006-12-20
- Last Posted Date
- 2012-04-20
- Lead Sponsor
- Novartis
- Target Recruit Count
- 11
- Registration Number
- NCT00414024
- Locations
- 🇻🇪
4 Investigative Sites, Venezuela, Venezuela
🇪🇬6 Investigative Sites, Egypt, Egypt
🇺🇸60 Investigative Sites, East Hanover, New Jersey, United States
Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without Steroids, in Adult Renal Transplant Recipients
- Conditions
- Renal Transplantation
- Interventions
- First Posted Date
- 2006-12-20
- Last Posted Date
- 2011-04-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 222
- Registration Number
- NCT00413920
- Locations
- 🇫🇷
C.H.U. La Milétrie, Poitiers, France